Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Major inclusion criteria~Diagnosis/Trial Population~* Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL):~  * history of diagnosis of CLL or SLL that meets IWCLL diagnostic criteria~ * histologically confirmed diagnosis of SLL by lymph node biopsy~ * indication for treatment as defined by the IWCLL guidelines~* Patients must have both of the following:~  * relapsed or refractory disease while receiving a BTKi therapy or intolerance of such therapy~ * single-agent or combination therapy with a BTKi for at least one month must be the patient's most recent prior anticancer therapy~* ECOG performance status of 0 to 2~* Patients with a past medical history of autologous or allogeneic stem cell transplantation must exhibit full hematological recovery~Laboratory Values~• Patients must meet adequate bone marrow function and adequate hepatic and renal function~Other Inclusion Criteria~• Females of childbearing potential must use a highly effective method of contraception~Major exclusion criteria~Diagnosis~• Patients who have:~* non-Hodgkin's lymphomas other than CLL/SLL~* transformed CLL/SLL or Richter's syndrome~* active and uncontrolled autoimmune cytopenia~Previous and Current Treatment~* Patients who have received treatment with a BTK inhibitor within 5 days prior to Day 1 dosing~* Patients who have, within 14 days prior to D1 dosing:~  * not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy~ * systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day with the exception of patients with signs of rapidly progressing disease~ * received live vaccines with the exception of vaccination against influenza with inactivated virus or for pneumococcal diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): tafasitamab (MOR208) in combination with idelalisib
- Cohort B (Type: EXPERIMENTAL): tafasitamab (MOR208) in combination with venetoclax

Based on this trial design, predict the completion outcome and termination type (if applicable).